Supplementary Table 2. Univariable analysis for predictors of recurrent acute myocardial infarction within 3 years

Variable	Odds ratio (95% CI)	*p* value
Age ≥ 75 yr	1.391 (1.086–1.782)	0.009
Women	1.393 (1.109–1.751)	0.004
Heart rate > 100 beats/min	1.412 (1.031–1.933)	0.031
Killip class III or IV	1.604 (1.216–2.117)	0.001
Hypotension (SBP < 100 mmHg)	0.855 (0.582–1.258)	0.428
Hypertension	1.422 (1.149–1.760)	0.001
Diabetes mellitus	1.853 (1.492–2.301)	< 0.001
Dyslipidemia	1.016 (0.727–1.420)	0.927
Previous heart failure	2.604 (1.303–5.204)	0.007
Previous CVA	1.302 (0.878–1.933)	0.190
Smoking	0.738 (0.598–0.912)	0.005
Renal dysfunction (Cr > 1.3 mg/dL)	1.952 (1.487–2.563)	< 0.001
Obesity (BMI > 25 kg/m^2)	0.939 (0.750–1.175)	0.583
Atypical chest pain	1.747 (1.332–2.291)	< 0.001
Family history of AMI	1.060 (0.701–1.605)	0.781
Target lesion location		
LM	1.869 (1.263–2.766)	0.002
LAD	1.442 (1.124–1.851)	0.004
LCx	1.234 (0.999–1.523)	0.051
RCA	1.166 (0.943–1.442)	0.155
Multivessel disease	1.636 (1.317–2.032)	< 0.001
Post-TIMI flow < III	0.884 (0.434–1.803)	0.735
Lesion type B2 or C	1.074 (0.782–1.477)	0.658
ST elevation MI	0.925 (0.749–1.142)	0.467
Total ischemic time > 12 hr	1.184 (0.959–1.462)	0.116
Ejection fraction < 50%	1.219 (0.980–1.514)	0.075
Maximum troponin I > 51.3	0.910 (0.701–1.180)	0.475
Atrial fibrillation	1.128 (0.627–2.029)	0.689
LDL-C ≥ 70 mg/dL or ≤ 50% reduction from baseline	0.935 (0.582–1.502)	0.780
Aspirin	NA	0.998
Prasugrel or ticagrelor	1.017 (0.809–1.278)	0.885
ACEi or ARB	0.814 (0.634–1.046)	0.108
Beta-blocker	0.894 (0.675–1.184)	0.434
Statin	0.743 (0.518–1.067)	0.108

CI, confidence interval; SBP, systolic blood pressure; CVA, cerebrovascular accident; Cr, creatinine; BMI, body mass index; AMI, acute myocardial infarction; LM, left main coronary artery; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction; MI, myocardial infarction; LDL-C, low-density lipoprotein cholesterol; NA, not applicable; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.